ASML valuation gap with US peers hits decade low By Investing.com

ASML is trading at its smallest premium to US chip-equipment peers in a decade, at about 37x next-12-month earnings and 31x next fiscal year earnings versus a 5-year average of 22x. The company remains the sole supplier of extreme ultraviolet lithography machines and raised its sales guidance for the year, but its shares are still lagging Applied Materials and Lam Research on a relative basis. The article is mainly a valuation and positioning update rather than a major fundamental catalyst.

Analysis

The key read-through is not that ASML is cheap on absolute terms, but that the market is no longer paying a scarcity premium for EUV exclusivity. That usually happens when investors start treating the equipment stack as a cycle-normalized AI infrastructure basket rather than a quasi-monopoly asset, which is a subtle but important regime shift: multiples compress even as end-demand improves. In that setup, the relative winner is often the broader capex ecosystem, while the single-name moat leader can underperform on valuation rerating.

The second-order effect is that this compression is a green light for peers to absorb more of the AI capex trade. If ASML’s premium keeps narrowing, portfolio flows may migrate toward AMAT and LRCX because they offer faster EPS leverage, more operating leverage to a recovery in wafer-fab spending, and less duration risk if AI digestion slows. That matters because the market is implicitly saying the next leg of the semiconductor cycle will be breadth, not just leading-edge node scarcity.

The main risk is timing mismatch: the valuation gap can stay open for months if ASML’s guidance credibility keeps improving and if investors continue to pay up for visible order quality. But if AI capex broadens beyond hyperscalers into logic/memory and packaging, ASML could re-rate back up on earnings revisions rather than multiple expansion; if not, its premium can keep eroding as a function of higher relative expectations. The contrarian point is that ASML may be less a “buy the dip” than a “still-expensive quality compounder” unless consensus underestimates how quickly peers can grow into their lower multiples.

Key Decisions for Investors

• Long AMAT / short ASML as a 3-6 month relative-value pair: capture further premium compression if the market continues rotating from monopoly quality into cyclical beta; stop if ASML re-accelerates orders and reclaims a >25% premium to AMAT.
• Long LRCX versus ASML for a 1-2 quarter trade: LRCX has more operating leverage to any broadening in memory and mature-node capex, so it should outperform if the AI spend theme widens beyond EUV bottlenecks.
• Buy ASML downside protection via 6-9 month put spreads instead of outright shorting: the stock still benefits from upward guidance revisions, but the valuation multiple is vulnerable if the next catalyst is merely “good,” not exceptional.
• Watch for a tactical entry in AMAT/LRCX on any post-earnings pullback in semis: use weakness to leg into exposure, because the current setup favors names with lower forward multiples and more room for estimate revisions over the next 2 quarters.